Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com
Negative Trials Fail to Dampen Enthusiasm for Adjuvant, Combination Therapy in RCC
October 10th 2022Toni K. Choueiri, MD, provides perspective on key research in renal cell carcinoma, including the first demonstration of benefit with triplet therapy in metastatic clear cell disease, the expansion of HIF-2α inhibition into the first line, and success with VEGF/immune-oncology approaches in the non–clear cell population.
Read More
Dostarlimab Plus Chemotherapy Meets ORR End Point in Metastatic Nonsquamous NSCLC
October 5th 2022The addition of dostarlimab to chemotherapy led to an improvement in objective response rate vs pembrolizumab plus chemotherapy in patients with newly diagnosed metastatic nonsquamous non–small cell lung cancer.
Read More
SCO-101 Plus FOLFIRI Will Continue to Be Studied Despite Missing Primary End Point in mCRC
October 4th 2022The addition of SCO-101 to FOLFIRI chemotherapy was safe and tolerable but failed to elicit a greater than 30% reduction in tumor volume in patients with metastatic colorectal cancer, though study of the combination will continue.
Read More
Pacritinib Improves Transfusion Independence, Anemia Through ACVR1 Inhibition in Myelofibrosis
October 3rd 2022Treatment with pacritinib led to an improvement in transfusion independence and hemoglobin in patients with myelofibrosis according to findings from a retrospective analysis of the phase 3 PERSIST-2 trial.
Read More
GB2064 Reduces the Level of Bone Marrow Fibrosis in Myelofibrosis
September 30th 2022Treatment with GB2064 monotherapy for at least 6 months led to a reduction in collagen fibrosis of the bone marrow of at least 1 grade in 4 of 5 evaluable patients with myelofibrosis, according to topline findings from a planned intermediate assessment of the phase 2a MYLOX-1 trial.
Read More
FDA Accepts NDA for 18F-rhPSMA-7.3 as Diagnostic Imaging Tool in Prostate Cancer
September 29th 2022The FDA has accepted for review a new drug application for 18F-rhPSMA-7.3, an investigational radiohybrid PSMA-targeted PET imaging agent for diagnostic imaging of prostate cancer, according to an announcement from Blue Earth Diagnostics.
Read More
Continuous Chemotherapy Improves TTF But Not OS in ER+/HER2- Advanced Breast Cancer
September 28th 2022Vinorelbine plus cyclophosphamide and capecitabine led to a significant improvement in time to treatment failure compared with paclitaxel alone in patients with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer.
Read More
Pembrolizumab Plus Chemotherapy Drives Durable PFS, OS Benefit in Squamous NSCLC
September 24th 2022Pembrolizumab plus chemotherapy demonstrated sustained improvements in progression-free survival and overall survival vs placebo plus chemotherapy in patients with treatment-naïve, metastatic squamous non–small cell lung cancer regardless of PD-L1 expression level.
Read More
Narsoplimab Elicits High Response Rate, Improves Organ Function in HSCT-TMA
September 23rd 2022Treatment with narsoplimab denoted high response rates and a significant improvement in laboratory thrombotic microangiopathy markers, translating to favorable overall survival in patients with hematopoietic stem cell transplantation–associated thrombotic microangiopathy.
Read More
ODAC Votes Against Poziotinib for HER2 Exon 20 Insertion–Mutated NSCLC
September 22nd 2022In a 9 to 4 vote, the FDA’s Oncologic Drugs Advisory Committee voted that the benefits of poziotinib do not outweigh its risks for the treatment of patients with HER2 exon 20 insertion–mutated non–small cell lung cancer.
Read More
Alpelisib Displays Clinical Benefit in Pediatric PIK3CA-Related Overgrowth Spectrum Disease
September 21st 2022Alpelisib decreased the need for surgery and led to improvements in performance status and disease-related signs and symptoms in pediatric patients with PIK3CA-related overgrowth spectrum disease who received treatment with the PI3K inhibitor under compassionate use.
Read More
Nivolumab Elicits Statistically Significant Improvement in RFS in Stage IIB/C Melanoma
September 15th 2022Adjuvant nivolumab monotherapy elicited a statistically significant and clinically meaningful improvement in recurrence-free survival compared with placebo for patients with completely resected stage IIB/C melanoma.
Read More
HRQoL Proves to Be Helpful Prognostic Factor for Cabozantinib/Nivolumab in Advanced RCC
September 14th 2022Higher baseline and longitudinal evaluations of health-related quality of life prior to and during treatment with nivolumab and cabozantinib demonstrated an association with improved progression-free survival and overall survival in patients with advanced, treatment-naïve renal cell carcinoma.
Read More
Obinutuzumab/Acalabrutinib/Venetoclax Triplet Misses the Mark in Relapsed/Refractory CLL
September 13th 2022Obinutuzumab, acalabrutinib, and venetoclax following optimal debulking with bendamustine failed to meet the prespecified rate of undetectable minimal residual disease in the peripheral blood at the end of induction treatment in patients with relapsed/refractory chronic lymphocytic leukemia.
Read More
Increased In-Situ and Immune Expression Enrich for Nivolumab/Ipilimumab Efficacy in Metastatic RCC
September 12th 2022The presence of more than 2 tertiary lymphoid structures coupled with increased density of Ki-67 and PD-1 positivity was shown to be associated with an increased response rate and prolonged progression-free survival with the combination of nivolumab and ipilimumab as frontline therapy in patients with metastatic renal cell carcinoma.
Read More
Advances in Breast and Gastrointestinal Cancers at ESMO 2022: Drs Rugo and Abou-Alfa
September 10th 2022OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Read More
Emavusertib Is Active in Heavily Pretreated AML and High-Risk MDS With Targeted Mutations
September 7th 2022Emavusertib elicited antitumor activity when given as a monotherapy in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndrome that harbored a spliceosome or FLT3 mutation.
Read More
Encorafenib/Cetuximab ± Binimetinib Improves Survival Regardless of Age in BRAF V600E–Mutant mCRC
August 30th 2022Treatment with either encorafenib plus cetuximab with or without binimetinib or standard chemotherapy each demonstrated comparable progression-free survival and overall survival in pretreated patients with BRAF V600E–mutated metastatic colorectal cancer.
Read More